Knockdown of KLK10 inhibits glucose metabolism and cell proliferation [92], suggesting that targeting KLK10 could downregulate GLUT1 via the PI3K/AKT/mTOR pathway, thereby inhibiting CRC growth [93]. The gene discussed is AKT1; the disease is colorectal carcinoma.